Arcos HH, González APM, Corona RP

Language: Spanish
References: 29
Page: 172-176
PDF size: 149.31 Kb.

ABSTRACT

Eclampsia occurs in 2 to 3% of women with preeclampsia with non-seizure prophylaxis, and up to 0.6% of women with preeclampsia without severity criteria. A therapeutic range of 4.8 to 8.4 mg/dL is recommended according to retrospective information. An observational, retrospective and descriptive study was conducted, taking as a sample those patients who have had hypertensive pregnancy disease with indication for the administration of magnesium sulfate as anticonvulsant prophylaxis, with impregnation dose with 4 g intravenous and 1 g/h maintenance with magnesium sulfate. A retrospective study was conducted in patients diagnosed with pregnancy-induced hypertensive disease who required treatment with magnesium sulfate as anticonvulsant prophylaxis and those who had taken serum magnesium levels, those which were later analyzed. Of the 66 patients treated with magnesium sulfate, 56 patients (84.4%) were found to have been in infratherapeutic levels, 10 patients (15.2%) at therapeutic levels, and no patients with supratherapeutic levels.

REFERENCES

1. Bell MJ. A historical overview of preeclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs. 2010; 39 (5): 510-518.

2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376 (9741): 631-44.

3. Khan K, Wojdyla D, Say L, Gülmezoglu A, Van Look P. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367 (9516): 1066-1074.

4. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008; 21 (5): 521-526.

5. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013; 347: f6564.

6. Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D et al. Short-term costs of preeclampsia to the United States health care system. S Am J Obstet Gynecol. 2017; 217 (3): 237-248.e16.

7. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004; 190 (6): 1520-1526.

8. Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses. 2014; 82 (5): 619-622.

9. Berhan Y, Berhan A. Should magnesium sulfate be administered to women with mild pre-eclampsia? A systematic review of published reports on eclampsia. J Obstet Gynaecol Res. 2015; 41 (6): 831-842.

10. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005; 105 (2): 402-410.

11. Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. J Neurol Sci. 2008; 271 (1-2): 158-167.

12. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. 1994; 309 (6966): 1395-1400.

13. Aagaard-Tillery KM, Belfort MA. Eclampsia: morbidity, mortality, and management. Clin Obstet Gynecol. 2005; 48 (1): 12-23.

14. Dahmus MA, Barton JR, Sibai BM. Cerebral imaging in eclampsia: magnetic resonance imaging versus computed tomography. Am J Obstet Gynecol. 1992; 167 (4 Pt 1): 935-941.

15. Al-Safi Z, Imudia AN, Filetti LC, Hobson DT, Bahado-Singh RO, Awonuga AO. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol. 2011; 118 (5): 1102-1107.

16. Zeeman GG, Cunningham FG. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. Am J Obstet Gynecol. 2014; 210 (4): 378-379.

17. ACOG Practice Bulletin No. 202 Summary: Gestational hypertension and preeclampsia. Obstet Gynecol. 2019; 133 (1): 211-214.

18. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The magpie trial: a randomised placebo-controlled trial. Obstet Gynecol. 2003; 101 (5): 1018.

19. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003; 101 (2): 217-220.

20. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004; 190 (6): 1520-1526.

21. Jain V. Letter to the editor: diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2015; 37 (9): 774-775.

22. Roberts JM, Villar J, Arulkumaran S. Preventing and treating eclamptic seizures. BMJ. 2002; 325 (7365): 609-610.

23. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010; (11): CD000025.

24. Chiarello DI, Marín R, Proverbio F, Coronado P, Toledo F, Salsoso R et al. Mechanisms of the effect of magnesium salts in preeclampsia. Placenta. 2018; 69: 134-139.

25. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev. 2010; (8): CD007388.

26. ACOG Practice Bulletin No. 202 Summary: gestational hypertension and preeclampsia. Obstet Gynecol. 2019; 133 (1): 211-214.

27. Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol. 1981; 57 (2): 199-202.

28. Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth. 2013; 13: 34.

29. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000; 38 (4): 305-314.